Evidence map›Paper›PMID 36411840›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2022

Antiliver Fibrosis Formula of Fuzheng Huayu Alleviates Inflammatory Response.

Qing-Qi Chang, Yi-Feng Pan, Jia-Yi Yang, Rong-Sheng Li, Chun-Lu Yuan, Ya-Fang Liao, Dan-Dan Zhang, Cheng-Hai Liu

Open access · hybridAbstract read
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Qing-Qi ChangInstitute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.ORCID https://orcid.org/0000-0002-8130-4369
Yi-Feng PanShanghai Huanghai Pharmaceutical Co. Ltd., Shanghai 200051, China.ORCID https://orcid.org/0000-0002-8967-0478
Jia-Yi YangInstitute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.ORCID https://orcid.org/0000-0001-7833-7787
Rong-Sheng LiShanghai Huanghai Pharmaceutical Co. Ltd., Shanghai 200051, China.ORCID https://orcid.org/0000-0002-9436-0343
Chun-Lu YuanInstitute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.ORCID https://orcid.org/0000-0003-1911-1408
Ya-Fang LiaoInstitute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.ORCID https://orcid.org/0000-0003-3470-1617
Dan-Dan ZhangInstitute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.ORCID https://orcid.org/0000-0003-0591-2167
Cheng-Hai LiuInstitute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.ORCID https://orcid.org/0000-0002-1696-6008
Shanghai University of Traditional Chinese Medicine · CNHuahai Pharmaceutical (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fuzheng Huayu's (FZHY) formula ameliorated liver fibrosis in clinical and experimental practice. Based on the close link between fibrosis and inflammation, its anti-inflammatory effect and related mechanisms were explored in this present study. With the aid of the inflammatory macrophage model, FZHY significantly blocked nitrite accumulation without observable cytotoxicity due to its suppression of inducible nitric oxide synthase (iNOS) gene and protein expressions in a concentration-depended manner. Proinflammatory mediators including IL-6, CD86, and CD40 were also restrained by FZHY. Interestingly, FZHY induced anti-inflammatory mediators heme oxygenase 1 (HO-1) and peroxisome proliferator-activated receptor

Identifiers

PMID36411840
PMCPMC9675606
OpenAlexW4309073154

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.